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Abstract
Bcl-2 and Bcl-X belong to a family of proteins overex-L
pressed in a variety of human cancers which inhibit
apoptosis in response to a number of stimuli including
chemotherapeutic agents and ionizing radiation. To bet-
ter understand the role of these polypeptides in modu-
lating the response of cancer cells to ionizing radiation
we used cell lines that were engineered to overexpress
the two polypeptides. Although Bcl-2 and Bcl-X over-L
expression resulted in inhibition of radiation-induced
apoptosis, it did not result in enhanced clonogenic
survival. Consistent with this was the observation that
Bcl-2 and Bcl-X protected cells from DNA fragmenta-L
tion, loss of mitochondrial membrane potential, and
caspase activation for up to 72 hours after irradiation.
Beyond 72 hours, there was a rapid loss in the ability of
Bcl-2 and Bcl-X to inhibit these markers of apoptosis.L
When Bcl-X was analyzed at 72 hours after irradiationL
and beyond, a rapid accumulation of a 16-kDa form of
Bcl-X was observed. To test the hypothesis that cleav-L
age of the 29-kDa form of Bcl-X by caspases to aL
16-kDa polypeptide results in its inability to inhibit
apoptosis beyond 72 hours, we constructed a cell line
that overexpressed a caspase-resistant form of Bcl-XL
( )Bcl-X -Dloop . Cells overexpressing Bcl-X -Dloop wereL L
resistant to apoptosis beyond 72 hours after irradiation
and did not contain the 16-kDa form at these time
points. In addition, Bcl-X -Dloop overexpression re-L
sulted in enhanced clonogenic survival compared with
control or Bcl-X overexpressing cells. These resultsL
provide a molecular basis for the observation that ex-
pression of Bcl-2 or Bcl-X is not a prognostic markerL
of tumor response to cancer therapy.
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Introduction
Eukaryotic cells respond to ionizing radiation by undergoing
cell cycle arrest to allow for DNA repair. In the event of
irreparable damage, irradiated cells can undergo pro-
grammed cell death or apoptosis. Our understanding of the
molecular events that lead to activation of the apoptotic
pathway in response to ionizing radiation is limited, although
numerous studies have demonstrated a requirement for p53
[ ]for efficient apoptosis 1,2 and the activation of zymogen
caspases as an essential step in radiation-induced apopto-
[ ]sis 3 . In addition, consistent with their function in regulating
apoptosis in response to various insults, overexpression of
[ ] [ ]Bcl-2 4 and Bcl-X 5 results in inhibition of radiation-in-L
duced apoptosis. Two primary activities have been as-
signed to Bcl-2 and Bcl-X in their function as inhibitors ofL
apoptosis. First, Bcl-2 and Bcl-X have been shown to beL
[ ]able to inhibit the activation of zymogen caspases 6,7 , and
second, they are able to protect the loss of mitochondrial
[ ]membrane potential 8 in response to various apoptotic
stimuli. Although apoptosis has been identified as an impor-
tant determinant of tumor growth as well as of response to
[ ]cancer therapy 9 , the role of Bcl-2 and Bcl-X expressionL
levels as predictive markers of clinical responsiveness is
unclear. Reports that Bcl-2 expression is indicative of a poor
prognosis have been contradicted by those that suggest an
improved prognosis by the presence of Bcl-2 overexpres-
[ ]sion 10–12 . Additionally, in-vitro studies on the role of
Bcl-2 in regulating sensitivity of cell lines to apoptosis in-
duced by chemotherapeutic agents as well as ionizing radi-
ation confirm the ability of Bcl-2 to inhibit apoptosis but fail
to demonstrate enhanced long-term survival of such cell
[ ]lines 13–15 .
To better understand the role of Bcl-2 and Bcl-X inL
cancer therapy, we used lymphoid as well as breast carci-
noma cells that were engineered to overexpress these two
proteins. Overexpression of Bcl-2 and Bcl-X resulted inL
inhibition of apoptosis induced by irradiation, but failed to
promote clonogenic survival. These results were consistent
with the observation that Bcl-2 and Bcl-X only inhibitedL
apoptosis for up to 72 hours after irradiation, after which
there was a time-dependent loss in protection from apopto-
sis. Coincident with the inability of Bcl-X to protect cellsL
from apoptosis, there was an appearance of active caspase
(3 and cleavage of Bcl-X to a 16-kDa form. Bcl-X -Dloop aL L
)caspase-resistant form of Bcl-X , on the other hand, pro-L
tected cells from apoptosis beyond 72 hours and was also
able to enhance clonogenic survival. These studies provide
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a molecular explanation for the often made observation that
Bcl-2 and Bcl-X only delay the onset of apoptosis.L
Materials and Methods
Cell Lines and Culture Conditions
(The MCF7 and Jurkat stable transfected cell lines Bcl2
)and Bcl-X used in this study have been described previ-L
[ ]ously 16 . The cells were maintained in RPMI 1640 contain-
ing 10% heat-inactivated fetal bovine serum, 1% L-gluta-
mine, 100 U/mL penicillin, and 100 mg/mL streptomycin at
378 in an atmosphere of 5% carbon dioxide. The transfected
( )Jurkat cell lines Bcl2 and Bcl-X were grown in the pres-L
(ence of 0.4 mg/mL Hygromycin Boehringer Mannheim,
)Indianapolis, IN . Wild-type Jurkat cells were treated with 25
(mmol/L ZVAD-fmk Enzyme System Products, Livermore,
)CA 24 hours before irradiation and again after it.
Irradiations
Freshly seeded Jurkat cells were irradiated at room tem-
perature with a 60Co source at 1 to 2 Gy/minutes. Dosit-
metry was carried out with an ionization chamber connected
to an electrometer system that was directly traceable to a
NIST standard. After irradiation, the cells were incubated for
the indicated time.
Cell Survival Assay
Cell survival was assessed with a standard clonogenic
assay. The survival curves were fitted by using a
linear-quadratic equation. The surviving fraction was calcu-
lated as the ratio of the mean inactivation dose under
control conditions divided by the mean inactivation dose
after radiation exposure.
Trypan Blue Assay
Acute viability was assessed by using trypan blue solu-
( ) ( )tion 0.4% Sigma, St. Louis, MO diluted in phos-
( ) ( )phate-buffered solution PBS after irradiation 10 Gy at the
indicated timepoints. A minimum of 300 cells were counted
for each sample, and the results were based on 4 indepen-
dent experiments.
Figure 1. Overexpression of Bcl - 2 and Bcl - X and ZVAD - fmk treat-L
ment promotes cell viability 48 hours after irradiation but fails to en-
( ) ( )hance clonogenic survival. A Bcl- X circles or Bcl- 2 triangles over-L (expressing Jurkat cells, as well as ZVAD-fmk–treated control di-
) ( )amonds and untreated control squares Jurkat cells were treated with
various doses of ionizing radiation. The fraction of cells surviving the
treatment was determined by plating a fixed number of cells onto dishes
to allow for colony formation. The data presented are derived from a
single experiment. Similar results were obtained from at least 3 indepen-
( )dent experiments. B Wild-type MCF-7 squares cells or Bcl- X over-L( )expressing MCF-7 cells circles were irradiated with various doses of
ionizing radiation, and the surviving fraction of cells was determined by
plating a fixed number of cells onto dishes to allow for colony formation.
( ) (C Wild-type Jurkat cells closed squares , as well as Bcl- 2 open
) ( )circles or Bcl- X open squares overexpressing and ZVAD-fmk–L ( )treated Jurkat cells closed circles were treated with various doses of
ionizing radiation, and cell viability was determined by trypan blue
exclusion 48 hours after irradiation.
Morphological Analysis
Apoptotic morphology was assessed by using a DNA
( 6)staining dye. Jurkat cells 1-2=10 were stained with
( )propidium iodide Sigma, St. Louis, MO . After irradiation
both treated and control cells were incubated for either 72
hours or 168 hours before staining. Cells were rinsed 2
times with PBS, fixed in 4% paraformaldehyde at room
temperature for 30 minutes, rinsed with PBS, and stained at
room temperature for 30 minutes in a 50 mg/mL solution of
propidium iodide in PBS. After staining, the cells were
rinsed 3 times with PBS, resuspended in a small volume of
PBS, 15 mL aliquots were transferred to glass slides, and
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cells were mounted by using Vectashield mounting medium
( )Vector Laboratories, Buringame, CA . Slides were exam-
ined immediately after staining with a Leitz Laborlux S
microscope. Apoptotic cells were quantitated based on nu-
clear morphology by using fluorescence microscopy, and
the percentage of apoptotic cells was calculated. A mini-
mum of 200 cells was counted for each sample, and each
experiment was done at least in duplicate.
Flow Cytometry
Jurkat cells were irradiated with 10 Gy of gamma radia-
tion. At the indicated time points, 2=106 cells were har-
vested, washed with PBS, fixed by dropwise addition of ice
cold 70% ethanol, and stored at 4 degrees until the day of
analysis. The cells were pelleted, washed with PBS, and
(stained with propidium iodide final concentration 20 ug/ml
)PI and 40 ug/ml Ribonuclease A in PBS . The samples
(were analyzed on a Coulter XL flow cytometer Coulter
)Electronics, Hialeah, FL . Trout erythrocyte nuclei were used
( )as an internal standard Biosure .
Mitochondrial Membrane Potential Assay
Jurkat cells 5=106 were either left untreated or treated
with 10 Gy of gamma radiation each day for the indicated
( )time points starting with the longest incubation 168 hours .
On the day of analysis, 2=106 cells for each sample were
removed, pelleted, and resuspended in 1 to 2 mL of PBS
(buffer containing 5 mg/mL rhodamine 123 Molecular
)Probes, Eugene, OR . Cells were incubated for 30 min at
378, washed with PBS, and resuspended in 0.5 mL of PBS
buffer containing 2 mg/mL propidium iodide. The samples
were analyzed immediately on a Coulter XL flow cytometer.
Bcl-X ImmunoblottingL
In each sample, 15=106 cells were either left untreated
or treated with 10 Gy of gamma radiation. At the indicated
( )timepoints 72, 144, and 192 hours cells were pelleted,
washed with PBS, and lysed with NP-40 lysis buffer contain-
(ing a protease inhibitor mixture Boehringer Mannheim, Indi-
)anapolis, IN . The lysates were assayed for protein concen-
(trations the Bio-Rad D protein assay kit Bio-Rad Laborato-c
)ries, Hercules, CA . After quantitation, an equal volume of
Laemmli buffer was added to each sample. The extracts
were then boiled for 5 minutes and 100 mg of protein was
loaded and resolved on a 15% sodium dodecyl sulfate
polyacrylamide gel electrophoresis. The resolved samples
(were transferred onto a nitrocellulose membrane Gelman
)Sciences, Ann Arbor, MI for Western blot analysis. The
Figure 2. Overexpression of Bcl - 2 and Bcl - X and ZVAD - fmk treat-L
ment inhibits apoptosis at 48 hours but not at 168 hours after irradiation.
Bcl- 2 or Bcl- X overexpressing, ZVAD-fmk–treated, or untreated,L
wild-type Jurkat cells received 10 Gy of ionizing radiation, and the
( )appearance of apoptotic morphology was examined after 48 hours A
( )and after 168 hours B . These data were averaged from 3 independent
experiments with the bars representing standard error. In parallel experi-
ments, the presence of apoptotic cells was identified by using propidium
iodide staining of ethanol- fixed cells, followed by flow analysis. The
appearance of cells having a less than G1 DNA content due to DNA
( )fragmentation was averaged from 3 experiments C .
presence of Bcl-XL cleaved and uncleaved products was
(detected by using a rabbit polyclonal antibody 1:500 dilu-
) ( ( )tion against Bcl-X Bcl-X L-19 , Santa Cruz Biotechnol-S/L
)ogy, Inc, Santa Cruz, CA and a horseradish peroxidase
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Figure 3. Bcl-2 and Bcl-X expression protects loss of mitochondrial membrane potential at 3 but not at 6 days afterL
ionizing radiation. Bcl-X overexpressing or wild-type Jurkat cells were irradiated with 10 Gy of ionizing radiation, afterL
which the cells were stained with Rh123 and propidium iodide and analyzed by flow. A. A decrease in Rh123 fluorescence
( )leftward shift on the X-axis is indicative of loss of mitochondrial membrane potential, whereas an increase in propidium
( )iodide staining upward shift on the Y-axis is indicative of loss of cell membrane integrity and hence viability. B. Data from
( )3 independent experiments were averaged "standard error . Wild-type Jurkat cells are shown by solid bars, Bcl-2
overexpressing cells with open bars, Bcl-X expressing cells with cross bars, and ZVAD-treated wild-type cells with doubleL
bars.
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( )HRP –conjugated secondary antibody. The blots were de-
(veloped by using a CL-HRP substrate system Pierce,
)Rockford, IL .
Results
Bcl-2 and Bcl-X Inhibit Radiation-Induced Apoptosis butL
Fail to Promote Long-Term Survival
To understand the contribution of apoptosis in
radiation-induced cell death we first investigated the impact
of Bcl-2 and Bcl-X expression on clonogenic survival ofL
Jurkat cells after ionizing radiation. In contrast to our initial
prediction, expression of Bcl-2 or Bcl-X did not significantlyL
( )alter the clonogenic survival of Jurkat cells Figure 1A .
Similarly, treatment of Jurkat cells with the caspase inhibitor
ZVAD-fmk also had no significant impact on clonogenic
( )survival Figure 1A compared with untreated Jurkat cells.
To examine if this was a cell line–specific phenomenon, we
studied clonogenic survival of MCF-7 cells in the presence
or absence of Bcl-X expression. As shown in Figure 1B,L
Bcl-X expression did not protect MCF-7 cells from radia-L
tion-induced clonogenic death. To test if the failure to en-
hance clonogenic survival under these conditions was due
to failure of Bcl-2, Bcl-X , and ZVAD-fmk to inhibitL
radiation-induced cell death, we performed a short-term
viability experiment. Control Jurkat cells, Bcl-2 or Bcl-XL
expressing Jurkat cells, and ZVAD-fmk–treated Jurkat cells
were irradiated, after which cell viability was measured by
trypan blue exclusion. Expression of Bcl-2 or Bcl-X , as wellL
as treatment with the caspase inhibitor ZVAD-fmk, resulted
in significant protection from radiation-induced cell death in
a dose-dependent manner, compared with untreated cells
( )Figure 1C .
We hypothesized that the discrepancy in these two re-
sults was due to the clonogenic survival assay requirement
of a 10 to 14 day period, in which a surviving cell has to
form a colony. However, in the viability assay, survival is
determined immediately by using trypan blue exclusion. To
further examine if Bcl-X and Bcl-2 are able to inhibitL
apoptosis in the short term but not in the long term, cells
were irradiated with 10 Gy, and the fraction of cells appear-
(ing morphologically apoptotic as visualized by the presence
)of condensed chromatin and pyknotic nuclei after 72 hours
or 168 hours was counted. As shown in Figure 2A, 22% of
Jurkat cells appeared morphologically apoptotic 72 hours
after irradiation, whereas Jurkat/Bcl-2 and Jurkat/Bcl-XL
cells appeared 4% and 3% apoptotic, respectively.
ZVAD-fmk treated cells were 10% apoptotic 72 hours after
irradiation. When the same cultures were analyzed for mor-
( )phological apoptosis 168 hours after irradiation Figure 2B ,
Jurkat cells appeared 45% apoptotic, whereas Bcl-2 and
(Bcl-X overexpressing cells appeared 25% apoptotic Fig-L
)ure 2B and ZVAD-fmk treated cells were 30% apoptotic.
The ability of Bcl-2 and Bcl-X to inhibit apoptosis byL
greater than 5-fold at the 72-hour timepoint and by less than
2-fold at the 168-hour timepoint is consistent with our hy-
pothesis that Bcl-2 and Bcl-X inhibit apoptosis in the shortL
term but not in the long term.
Bcl-2 and Bcl-X Delay but Do Not Prevent DNA Fragmen-L
tation, Loss of Mitochondrial Membrane Potential, and Cas-
pase-3 Activation
The results just discussed were substantiated when hy-
( )podiploidy was used as a measure of apoptosis Figure 2C .
Bcl-2 and Bcl-X overexpression as well as ZVAD-fmkL
(treatment resulted in inhibition of DNA fragmentation as
determined by the presence of cells having a less than G1
)content of DNA , 3 but not 7 days after irradiation. Bcl-XL
and Bcl-2 mediate their antiapoptotic effect by 2 mecha-
nisms. First, Bcl-X protects the loss of mitochondrial mem-L
brane potential, and second, Bcl-X inhibits activation ofL
caspases. To test if the loss of Bcl-X ’s ability to inhibitL
radiation-induced apoptosis at day 7 was consistent with the
loss of these functions, we performed the following experi-
ments. Using rhodamine 123 fluorescence as a marker for
mitochondrial membrane potential and propidium iodide
(staining as marker for cell membrane integrity and there-
)fore cell viability , we demonstrated that 45% of Jurkat cells
(lost their mitochondrial membrane potential as evidenced
)by a decrease in Rh123 fluorescence and were nonviable
( )as evidenced by increased propidium iodide staining 72
( )hours after irradiation Figure 3A and B . Bcl-X overex-L
pression resulted in only 17% of Jurkat/Bcl-X cells losingL
(their mitochondrial membrane potential at day 3 Figure 3A
)and B . Similarly, Bcl-2 expression also inhibited
radiation-induced loss of mitochondrial membrane otential
and apoptosis 3 days after irradiation. The ability of Bcl-2
and Bcl-X to protect mitochondrial dysfunction was lostL
Figure 4. Cleavage of Bcl - X and caspase 3 activation is initiated 72L
hours after irradiation. Bcl- X overexpressing Jurkat cells were irradi-L
ated with 10 Gy of ionizing radiation, and cell extracts were prepared at
various times and analyzed by Western blot for the presence of Bcl- XL( ) ( )cleavage A and caspase 3 activation B .
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beyond day 6. ZVAD-fmk treatment also resulted in inhibi-
tion of loss of mitochondrial membrane potential, although
to a much lesser extent. Interestingly, Bcl-2 inhibited apop-
tosis as late as day 5, at which point Bcl-X and ZVAD-fmkL
( )had lost their inhibitory capacity Figure 3B .
Recent reports have suggested that cleavage of Bcl-2, as
well as Bcl-X , by caspases can result in loss of functionL
[ ]17–19 . To examine if loss of Bcl-X function at the laterL
timepoints in response to ionizing radiation correlated with
its cleavage, we performed Western blot analysis of Jurkat/
Bcl-X cells. Untreated cells or irradiated cells were har-L
vested at the indicated timepoints and analyzed. As shown
in Figure 4A, 72 hours after irradiation an additional Bcl-XL
immunoreactive band was detected at 16 kDa. This form of
( )Bcl-X was undetectable in untreated cells Figure 4A , asL
Figure 5. Bcl - X -D loop but not Bcl - X is resistant to cleavage byL L
caspases and is able to inhibit apoptosis in the short - and long-term
assays. Jurkat cells overexpressing Bcl- X or Bcl- X -D loop were irra-L L
diated with 10 Gy of ionizing radiation, and at various times cells were
collected for the preparation of cell extracts for Western blot analysis
( )with a Bcl- X –specific antibody A . At these times cells were alsoL ( )collected for determination of cell viability with trypan blue exclusion B .
Control cultures that were mock irradiated were also analyzed in paral-
( )lel. Data presented in B are an average of 4 experiments, with bars
representing standard error.
Figure 6. Bcl - X -D loop– expressing Jurkat cells have an improvedL
clonogenic survival in response to ionizing radiation, compared with
( )Jurkat cells or Jurkat/Bcl- X cells. Jurkat cells squares , Jurkat/Bcl- XL L( ) ( )cells circles , or Jurkat/Bcl- X -D loop cells triangles were irradiatedL
with various doses of ionizing radiation and immediately plated onto
dishes for the determination of the surviving fraction. Bcl- X -D loop–L
overexpressing cells were much more resistant to ionizing radiation and
resulted in a much larger fraction of surviving cells at all doses of
radiation. Similar results were obtained from 3 independent experi-
ments, and the data presented are from a representative experiment.
(well as 24 hours and 48 hours after irradiation data not
)shown . The 16-kDa band accumulated in a time-dependent
manner. Interestingly, detection of the 16-kDa form of Bcl-XL
(coincided with the appearance of active caspase 3 Figure
)4B . Caspase 3 is a zymogen that is cleaved to a 2-chain
polypeptide during apoptosis, resulting in its functional acti-
vation. The cleaved form of caspase 3 was undetectable in
( )nonirradiated cells Figure 4B or at 24 and 48 hours after
( )irradiation of Jurkat/Bcl-X cells data not shown . Cleaved,L
active caspase was readily detectable 72 hours after irradia-
tion and accumulated at 144 and 192 hours. The appear-
ance of the 16-kDa form of Bcl-X mirrored the activation ofL
caspase 3, suggesting that activation of caspase 3 resulted
in cleavage of Bcl-X to a 16-kDa protein. Taken together,L
these results indicate that expression of Bcl-X results inL
inhibition of radiation-induced apoptosis in the short term
( )up to 72 hours , but subsequent cleavage and inactivation
of Bcl-X results in loss of protection from apoptosis.L
Role of Caspases in the Cleavage and Inactivation of Bcl-XL
To directly test the role of caspases in the inactivation of
Bcl-X , we used a mutant of Bcl-X that lacks the caspaseL L
( ) [ ]recognition sequence Bcl-X -Dloop 20 . Bcl-X -DloopL L
cannot be cleaved but still retains antiapoptotic function.
Jurkat cells were stably transfected with the expression
vector for Bcl-X -Dloop to derive the Jurkat/Bcl-X -DloopL L
cell line. When cell extracts from irradiated Jurkat/Bcl-XL
and Jurkat/Bcl-X -Dloop cells were analyzed by WesternL
blot, Bcl-X was detected as a 29-kDa polypeptide at theL
( )24-and 48-hour timepoints data not shown . As before,
Bcl-X was also detected as a 16-kDa polypeptide 72 andL
(144 hours after irradiation but not in the absence of irradia-
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)tion , whereas Bcl-X -Dloop was not cleaved to the 16-kDaL
( )species at these times after irradiation Figure 5A . Next, we
examined the ability of Bcl-X -Dloop to protect cells fromL
cell death at different times after irradiation compared to
wild-type Bcl-X . As shown in Figure 5B, Bcl-X -loop, unlikeL L
wild type Bcl-X , was able to protect cells from radiation-in-L
( )duced cell death at early 24 and 48 hours as well as late
( )timepoints beyond 72 hours . The ability of Bcl-X -Dloop toL
protect cells from radiation-induced cell death also resulted
in enhanced clonogenic survival of cells expressing the
caspase-resistant mutant of Bcl-X , compared with cellsL
expressing the wild-type molecule or cells that were trans-
( )fected with the vector only Figure 6 .
Discussion
Our studies on understanding the role Bcl-2 and Bcl-X playL
in determining the radiosensitivity of tumor cells led to the
observation that expression of these antiapoptotic proteins
results in inhibition of apoptosis when assays that measure
apoptosis within 72 hours after irradiation are used. In
contrast, when apoptosis was measured 96 hours or more
after irradiation or with either a clonogenic assay, a morpho-
logical assay, or a cell viability assay, the ability of Bcl-2 and
Bcl-X to inhibit radiation-induced apoptosis was greatlyL
diminished. Inability of these proteins to block apoptosis in
the long term has been observed in response to many
[ ]stimuli. Bissonnette et al. 21 observed that in Chinese
hamster ovary cells undergoing c-myc–induced apoptosis,
Bcl-2 expression resulted in a temporary delay but did not
[ ]inhibit apoptosis. Yin and Schimke 14 also observed that
Bcl-2 expression inhibited apoptosis in response to colec-
imid, aphidicolin, and trimetrexate treatment when short-term
assays of apoptosis were used, such as determination of
nuclear morphology after propidium iodide staining and vital
dye exclusion. In contrast, when a clonogenic assay was
used to measure cell viability, Bcl-2 expression did not
appear to protect cells from these insults. Kyprianou et al.
[ ]13 also observed that Bcl-2 expression rendered prostate
cancer cells resistant to radiation-induced apoptosis but
failed to enhance clonogenic survival. A number of possible
explanations for the discrepancy in the role of Bcl-2 in
inhibiting apoptosis by clonogenic assays compared with
short-term assays have been put forward. Yin and Schimke
[ ] [ ]14 , as well as Kyprianu et al. 13 , suggested that this
inconsistency could be due to the fact that Bcl-2 may not
[ ]inhibit apoptosis but simply delay it. Milner et al. 22 con-
cluded that Bcl-2 expression results in inhibition of apopto-
sis in irradiated B-lymphoma–derived cells when short-term
assays but not long-term assays are used, because Bcl-2
can also promote apoptosis through its ability promote
[ ]growth arrest. Lock and Stribinskiene 15 proposed that the
ability of Bcl-2 to prevent apoptosis may not translate into
increased survival in response to etoposide treatment be-
cause Hela cells respond to etoposide either by apoptosis
or by mitotic catastrophe. Cells that are protected from
apoptosis by Bcl-2 expression fail to survive in the long term
owing to mitotic death.
To understand the molecular basis of the failure of Bcl-2
and Bcl-X to protect cells from undergoing apoptosis atL
( )later timepoints beyond 96 hours , we examined the key
activities of these proteins over time. Two primary activities
have been ascribed to Bcl-2 and its homologues, such as
Bcl-X . First, in an Apaf-1–dependent manner, Bcl-2–likeL
[ ]proteins can inhibit activation of caspases 23 . Second, the
ability of Bcl-2–like proteins to inhibit loss of mitochondrial
[ ]membrane potential is also key to their function 23 . Our
results indicate that despite the presence of Bcl-X , irradia-L
tion of Jurkat cells resulted in activation of caspase 3 at 72
hours. In addition, despite the presence of Bcl-2 and Bcl-X ,L
irradiation of Jurkat cells resulted in the loss of mitochon-
drial membrane potential, although in a much more delayed
time course compared with control cells. Inability of Bcl-2 or
Bcl-X to protect cells from apoptosis in the long term isL
consistent with the inability of these proteins to completely
inhibit caspase activation or to protect the loss of mitochon-
drial membrane potential in the long term. This, therefore,
suggested to us that Bcl-2 and Bcl-X must be nonfunc-L
tional at these timepoints. Based on previous observations
[ ]17–19 that both these proteins can be cleaved and inacti-
vated during apoptosis, we investigated whether during radi-
ation-induced apoptosis, cleavage of Bcl-X was occurring.L
Indeed, approximately 72 hours after irradiation, a 16-kDa
form of Bcl-X was detected in cell extracts, and this contin-L
ued to accumulate with time. Analysis of Bcl-2 also revealed
the appearance of an approximately 22-kDa polypeptide at
( )96 hours after irradiation data not shown . Appearance of
the cleaved form of Bcl-X and Bcl-2 coincided with theirL
inability to protect cells from radiation-induced apoptosis. In
addition, cleavage of Bcl-X was coincident with the pres-L
ence of active caspase 3 at 72 hours. This is consistent with
published results that the 16-kDa form of Bcl-X appearsL
upon cleavage of Bcl-X at an aspartic acid residue atL
[ ]position 61 17 . The report also demonstrated that the
16-kDa form of the protein, which lacks the BH4 domain,
has proapoptotic activity rather than antiapoptotic activity,
similar to Bcl-X . We believe that in our system, in re-S
sponse to the appearance and accumulation of the cleaved
protein, there was a corresponding increase in the rate of
apoptosis.
Recent reports that the cleavage of Bcl-2 by caspases
[ ]also results in a polypeptide with proapoptotic activity 18
further validates our hypothesis that failure to protect cells
from radiation-induced apoptosis in the long term is due to
cleavage of antiapoptotic proteins such as Bcl-2 and Bcl-X .L
To test the role of caspases in inactivating Bcl-X , weL
irradiated Bcl-X expressing and nonexpressing Jurkat cellsL
and monitored cell viability over time in the presence or
absence of caspase inhibitors. Although the expression of
Bcl-X protected Jurkat cells from cell death over the first 72L
hours, we consistently observed an acceleration in the rate
of apoptosis beyond this time, which we propose is due to
inactivation of Bcl-X by caspases. This acceleration in theL
rate of apoptosis was greatly inhibited in the presence of
( )caspase inhibitors ZVAD-fmk, data not shown , suggesting
that inhibition of caspases prevented the cleavage of Bcl-X ,L
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which therefore retained its antiapoptotic function. To di-
rectly test the role of caspases in the cleavage and inactiva-
tion of Bcl-X , a deletion mutant that lacks a caspaseL
recognition sequence and hence a noncleavable form of
( ) [ ]Bcl-X Bcl-X -Dloop was used 20 . Expression ofL L
Bcl-X -Dloop resulted in protection of cells from apoptosis inL
the short term as well as long term and also enhanced
clonogenic survival. These studies provide a definitive ex-
planation for a number of previous observations that indi-
cated that the antiapoptotic proteins Bcl-2 and Bcl-X sim-L
ply delay the induction of apoptosis.
We believe our results also provide a molecular explana-
tion for numerous studies that failed to demonstrate a corre-
lation between expression of antiapoptic proteins such as
Bcl-2 in tumors and a poor clinical prognosis. In some
reports, expression of Bcl-2 was associated with improved
[ ]prognosis 10–12 . Based on previous reports that the cas-
pase cleaved form of Bcl-2 has proapoptotic activity and
based on results presented here, it is not difficult to imagine
how a Bcl-2 overexpressing tumor would respond better to
therapy. Further studies to test the impact of Bcl-2, Bcl-X ,L
and Bcl-X -Dloop expression on tumor response duringL
radiation treatment as well as during chemotherapy are in
progress and will enable the evaluation of the role of Bcl-XL
cleavage in vivo.
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